 REDWOOD CITY, Calif., Sept. 07, 2021 GLOBE NEWSWIRE -- Revolution Medicines, Inc. Nasdaq: RVMD, a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the companys chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference. 